US equities |
META $620.19 ▼-1.64% MU $928.76 ▲+2.77% NVDA $217.94 ▲+0.90% TSLA $407.46 ▲+4.04% SPCX $148.58 ▲+1.14% AAPL $347.10 ▲+0.93% AMD $560.26 ▲+5.45% MSFT $531.33 ▼-0.24%
FinancialContent

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

3.220 +0.300 (+10.27%)
Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Study Results Supporting Potential Utility of DehydraTECH-CBD in Diabetes Control
Via Investor Brand Network
Topics Animal Testing Intellectual Property
News headline image
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
Via Investor Brand Network
Topics Regulatory Compliance
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
Via CannabisNewsWire
Topics Regulatory Compliance
News headline image
Positive Results from Lexaria's Molecular Characterization Study
Via ACCESSWIRE
News headline image
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
Via ACCESSWIRE
News headline image
Lexaria Preparing For Strategic Growth
Via ACCESSWIRE
News headline image
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
Via ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Work with Tirzepatide Molecule
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Oral GLP-1 Alternatives for Diabetes and Obesity Treatment
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Q3 2024 Financial Results; Offers a Roadmap for its Key GLP-1 Study Program
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments
Via CannabisNewsWire
News headline image
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases “Noteworthy” Weight-Loss Results from Recent Animal Study
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Produces Notable Findings in Latest Weight Loss Study
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Issuance of Three New Patents, Growing Portfolio to 46 Granted Patents Worldwide
Via Investor Brand Network
Topics Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study
Via Investor Brand Network
News headline image
LEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024 ↗
LEXX stock results show that Lexaria Bioscience missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024. 
Via InvestorPlace
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy
Via Investor Brand Network
Topics Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Favorable Strategic Partnering with Leading GLP-1 Players
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2; Set to Complete Third Study Arm in Early July
Via Investor Brand Network
News headline image
7 A-Rated Penny Stocks to Beat June Gloom ↗
Some penny stocks can be diamonds in the rough. These A-rated penny stocks are all solid picks for a portfolio this month. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >